This inventor holds 6 USPTO granted patents. Top assignees: Spofa United Pharmaceutical Works, Spofa, Pharmaceutical Works, Spofa, United Pharmeceutical Works. Active years: 1976-1982.
Company Filing History:
4 out of 8 
1 out of 1 
1 out of 1 Years Active: 1976-1982
Title: Miroslav Seda: Innovator in Pharmaceutical Chemistry
Introduction
Miroslav Seda is a notable inventor based in Prague, Czech Republic. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative patents. With a total of 6 patents to his name, Seda has focused on developing novel compounds with potential therapeutic applications.
Latest Patents
Among his latest patents, Seda has developed alkyl cyanomethyl ergoline-I derivatives and salts thereof. This patent describes a procedure for the preparation of a new group of alkyl cyanomethyl ergoline-I derivatives and pharmaceutically acceptable salts. The compounds are characterized as D-6-alkyl-8-cyanomethylergoline-I derivatives, where R represents an alkyl group of 2-4 carbon atoms. Another significant patent involves D-6-allyl-8-ergol-I-ylacetamide, which outlines a process for preparing novel 6-substituted derivatives of D-8-ergolin-I-ylacetamide and their pharmaceutically acceptable addition salts. This composition demonstrates superior antilactation and antinidation characteristics compared to prior art compounds.
Career Highlights
Miroslav Seda has worked with prominent companies in the pharmaceutical industry, including Spofa United Pharmaceutical Works and Spofa. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.
Collaborations
Throughout his career, Seda has collaborated with notable colleagues such as Miroslav Semonsky and Karel Rezabek. These partnerships have contributed to his success and the advancement of his research.
Conclusion
Miroslav Seda's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an innovator in the field. His work continues to influence the development of new therapeutic compounds.